We are excited to announce that Sri Lanka has joined the global initiative, Advancing Evidence for the Global Implementation of Spatial Repellents (AEGIS) in 2022. And the aim of the program is to generate further evidence about an innovative new tool, spatial repellents, to help prevent vector-borne diseases like dengue. The project is managed by the University of Notre Dame, USA, and monitored by FHI Clinical, global clinical research organisation, with funding from Unitaid. It is significant to note that the sociological impact of this project is handled through a study conducted by Johns Hopkins University, Bloomberg School of Public Health. This is a significant milestone in our ongoing efforts to combat the spread of Dengue, a disease that affects many people in Sri Lanka. This is the first ever, community based large-scale clinical trial in Asia to quantify the protective efficacy of a Spatial Repellent product.
As a member of this program, Sri Lanka will gain access to the latest research and technology in mosquito control, and we will be able to share our own experiences and expertise with the global community. We hope that our participation in this program will contribute towards achieving our goal of eradicating dengue from our country. Sri Lanka has successfully eradicated malaria in 2016.
We at RemediumOne are committed to working with our partners to find solutions to public health challenges, and we look forward to continuing our efforts to improve the lives of people in Sri Lanka and around the world.